ABSTRACT
The outcome of subset analysis to guide practice, particularly in diabetics, saphenous vein grafts, and small vessels, is awaited.
In selected patients, a strategy of direct stenting is feasible and safe and is economically attractive, compared to the conventional approach of pre-dilatation followed by stenting. The current evidence base suggests a low incidence of associated adverse events and comparable outcome data in the acute 6-month setting to the later. The basic principle of correct lesion, patient and stent selection remains as important as ever.
